Clinical trials: Neoplasms, pill or tablet or capsule or oral, open to volunteers
Multiple Myeloma, Smoldering Multiple Myeloma
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk…
- Trial name
- iStopMM (NCT03815279)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- Iceland
- Volunteers
- 80 people
- Sponsor
- Landspitali University Hospital
Advanced Solid Tumor, Metastatic Solid Tumor
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human Phase 1a/b, open-label, multicenter, dose escalation, optimization and expansion study of ISM5939 to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of ISM5939 in patients…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors
- Trial name
- NCT06724042
- Testing
- ISM5939, Cisplatin, Docetaxel
- Volunteers
- 159 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07545213
- Testing
- SKB264
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Advanced Solid Tumor
A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
The purpose of this study is to test if the BG-92505 is safe and if it works in patients with advanced solid tumors when it is given on its own or in combination with anti-cancer agents.
- Trial name
- NCT07896460
- Testing
- BG-92505, Anti-Cancer Agent
- Volunteers
- 137 people
- Sponsor
- BeOne Medicines
Breast Cancer
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%.
- Trial name
- NCT04646759
- Testing
- Fulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Solid Tumors With FGFR2 Alterations, Adult
A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic…
- Trial name
- NCT06800196
- Testing
- KNT-0916
- Where
- China
- Volunteers
- 151 people
- Sponsor
- KinoTeck Therapeutics Co., Ltd
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Relapsed Acute Myeloid Leukemia
Imetelstat Combinations in Relapsed AML
IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML.
- Trial name
- IMAGINE (NCT07320235)
- Testing
- Imetelstat, Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Douglas Tremblay
Glioblastoma, Glioblastoma Multiforme
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM
- Trial name
- NCT05271240
- Testing
- Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Northwell Health
Myelodysplastic Syndromes, High Risk
Sonrotoclax Plus Azacitidine in Patients With MDS-IB2
This study will evaluate the safety and preliminary effectiveness of sonrotoclax combined with azacitidine in adults aged 18-70 years with newly diagnosed myelodysplastic neoplasms with increased blasts-2 (MDS-IB2).
- Trial name
- NCT07885397
- Testing
- Sonrotoclax, Azacitidine (AZA)
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Adult
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
- Trial name
- NCT05133882
- Testing
- Clifutinib Besylate
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Prostate Cancer, Localized Prostate Carcinoma
Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle
Radiotherapy is a standard and highly effective treatment for prostate cancer that is confined to the prostate gland. One modern approach, called stereotactic body radiotherapy (SBRT), delivers treatment in just five sessions and…
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma, Low-Risk Prostate Cancer, Intermediate-risk Prostate Cancer
- Trial name
- EF-PRESERVE (NCT07916779)
- Testing
- Daily Adaptive MR-Enhanced SBRT with Neurovascular Bundle Sparing
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative…
- Trial name
- NCT06935188
- Testing
- Dalpicilib combined with cetuximab, cetuximab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Hepatocellular Carcinoma, Hepatocellular Cancer
Patients With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage, resulting in limited therapeutic options.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Liver Diseases, Liver Cancer
- Trial name
- FORCE (NCT07690683)
- Testing
- Fecal microbiota transplantation performed via colonoscopy.
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Brain Metastasis From Advanced HER2-negative Breast Cancer
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and…
- Trial name
- NCT06839560
- Testing
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, Early Onset Colorectal Cancer
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally. CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants…
- Conditions
- Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
- Trial name
- DEMETRA (NCT05732623)
- Testing
- Semi Quantitative Food Frequency Questionnaire (SQFFQ)
- Where
- 8 sites in United States, Finland and 4 more
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Relapsed or Advanced Non-small Cell Lung Cancer
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the…
- Trial name
- NCT05503888
- Testing
- Almonertinib combined with SHR-1701, Almonertinib
- Volunteers
- 160 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Polycystic Ovary Syndrome (PCOS)
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
This study will investigate brown adipose tissue-related physiological responses in women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT07896642
- Testing
- inositol
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istanbul Health and Technology University
Bone Sarcomas
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
- Trial name
- NCT07193550
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.